Can a targeted pill tame a rare immune disease?

This phase 2 trial is testing whether the experimental drug luvometinib, taken alone or with the chemotherapy drug cytarabine, can control Langerhans cell histiocytosis—a rare disease where immune cells build up and damage tissues. People aged 10 and older who need systemic treatment will receive luvometinib for six cycles. If their disease responds well, they continue on luvometinib alone; if not, they may also get cytarabine. The study aims to see how many participants achieve a significant reduction in disease activity.